Journal of Neurology

, Volume 259, Issue 8, pp 1519–1529 | Cite as

Interleukin-1A −889C/T polymorphism and risk of Alzheimer’s disease: a meta-analysis based on 32 case–control studies

  • Xue Qin
  • Qiliu Peng
  • Zhiyu Zeng
  • Zhiping Chen
  • Liwen Lin
  • Yan Deng
  • Xiamei Huang
  • Juanjuan Xu
  • Huiling Wu
  • Shan Huang
  • Shan Li
  • Jinmin Zhao


The Interleukin-1A (IL-1A) −889C/T polymorphism has been reported to be associated with Alzheimer’s disease (AD) susceptibility, but the results of these previous studies have been inconsistent. The aim of this study was to explore whether the IL-1A −889C/T polymorphism confers susceptibility to AD. All studies published up to July 2011 on the association between the IL-1A −889C/T polymorphism and AD risk were identified by searching electronic databases PubMed, Embase and Alzgene. The association between the IL-1A −889C/T polymorphism and AD risk was assessed by odds ratios (ORs) together with their 95% confidence intervals (CIs). A total of 32 case–control studies including 7,046 AD cases and 7,534 controls were eventually identified. Overall, positive associations of the IL-1A −889C/T polymorphism with AD risk were found in allele comparison T versus C (OR = 1.019, 95% CI= 1.027–1.198), recessive model TT versus CT  + CC (OR = 1.278, 95% CI = 1.073–1.522) and dominant model TT + CT versus CC (OR = 1.102, 95% CI = 1.013–1.200). In subgroup analysis stratified by ethnicity, significant associations were demonstrated in Caucasians but not in Asians. In subgroup analysis according to the age of onset, no significant association was detected. The present meta-analysis suggests that the IL-1A is a candidate gene for AD susceptibility. The IL-1A −889C/T889C/T polymorphism may be a risk factor for AD in Caucasians. Further investigations taking the APOE ε4 status and other confirmed genetic factors and potential gene–gene and gene–environmental interactions into consideration for this polymorphism should be conducted.


Alzheimer’s disease Interleukin-1A Polymorphism Meta-analysis 



Hardy–Weinberg equilibrium


Odds ratio


Confidence interval


  1. 1.
    Blomqvist ME, Reynolds C, Katzov H, Feuk L, Andreasen N, Bogdanovic N, Blennow K, Brookes AJ, Prince JA (2006) Towards compendia of negative genetic association studies: an example for Alzheimer disease. Hum Genet 119:29–37PubMedCrossRefGoogle Scholar
  2. 2.
    Bosco P, Gueant-Rodriguez RM, Anello G, Romano A, Namour B, Spada RS, Caraci F, Tringali G, Ferri R, Gueant JL (2004) Association of IL-1 RN*2 allele and methionine synthase 2756 AA genotype with dementia severity of sporadic Alzheimer’s disease. J Neurol Neurosurg Psychiatry 75:1036–1038PubMedCrossRefGoogle Scholar
  3. 3.
    Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F, Crook JE, Pankratz VS, Dickson DW, Graff-Radford NR, Petersen RC, Morgan K, Younkin SG (2010) Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol 67:961–964PubMedCrossRefGoogle Scholar
  4. 4.
    Clarimon J, Bertranpetit J, Calafell F, Boada M, Tarraga L, Comas D (2003) Joint analysis of candidate genes related to Alzheimer’s disease in a Spanish population. Psychiatr Genet 13:85–90PubMedGoogle Scholar
  5. 5.
    Combarros O, Infante J, Llorca J, Berciano J (2004) No evidence for association of the monocyte chemoattractant protein-1 (−2518) gene polymorphism and Alzheimer’s disease. Neurosci Lett 360:25–28PubMedCrossRefGoogle Scholar
  6. 6.
    Combarros O, Llorca J, Sanchez-Juan P, Mateo I, Infante J, Rodriguez E, Sanchez-Quintana C, Berciano J (2007) Interaction between prion protein and interleukin-1A genes increases early-onset Alzheimer’s disease risk. J Neurol 254:115–117PubMedCrossRefGoogle Scholar
  7. 7.
    Combarros O, Sanchez-Guerra M, Infante J, Llorca J, Berciano J (2002) Gene dose-dependent association of interleukin-1A [−889] allele 2 polymorphism with Alzheimer’s disease. J Neurol 249:1242–1245PubMedCrossRefGoogle Scholar
  8. 8.
    Corder EH, Blennow K, Prince JA (2008) Genetic susceptibility sets for Alzheimer’s disease identified from diverse candidate loci. Rejuvenation Res 11:667–679PubMedCrossRefGoogle Scholar
  9. 9.
    Cousin E, Mace S, Rocher C, Dib C, Muzard G, Hannequin D, Pradier L, Deleuze JF, Genin E, Brice A, Campion D (2011) No replication of genetic association between candidate polymorphisms and Alzheimer’s disease. Neurobiol Aging 32:1443–1451PubMedCrossRefGoogle Scholar
  10. 10.
    Deniz-Naranjo MC, Munoz-Fernandez C, Alemany-Rodriguez MJ, Perez-Vieitez MC, Aladro-Benito Y, Irurita-Latasa J, Sanchez-Garcia F (2008) Cytokine IL-1 beta but not IL-1 alpha promoter polymorphism is associated with Alzheimer disease in a population from the Canary Islands, Spain. Eur J Neurol 15:1080–1084PubMedCrossRefGoogle Scholar
  11. 11.
    Drzezga A, Grimmer T, Henriksen G, Muhlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschlager A, Riemenschneider M, Wester HJ, Foerstl H, Schwaiger M, Kurz A (2009) Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72:1487–1494PubMedCrossRefGoogle Scholar
  12. 12.
    Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmuller F, Muller U, Kurz A, Zimmer R, Evans RM, Hake A, Gasser T, Oertel WH, Griffin WS, Paul SM, Farlow MR (2000) Association of an interleukin 1 alpha polymorphism with Alzheimer’s disease. Neurology 55:480–483PubMedCrossRefGoogle Scholar
  13. 13.
    Dursun E, Gezen-Ak D, Ertan T, Bilgic B, Gurvit H, Emre M, Eker E, Engin F, Uysal O, Yilmazer S (2009) Interleukin-1alpha -889 C/T polymorphism in Turkish patients with late-onset Alzheimer’s disease. Dement Geriatr Cogn Disord 27:82–87PubMedCrossRefGoogle Scholar
  14. 14.
    Emahazion T, Feuk L, Jobs M, Sawyer SL, Fredman D, St Clair D, Prince JA, Brookes AJ (2001) SNP association studies in Alzheimer’s disease highlight problems for complex disease analysis. Trends Genet 17:407–413PubMedCrossRefGoogle Scholar
  15. 15.
    Fidani L, Goulas A, Mirtsou V, Petersen RC, Tangalos E, Crook R, Hardy J (2002) Interleukin-1A polymorphism is not associated with late onset Alzheimer’s disease. Neurosci Lett 323:81–83PubMedCrossRefGoogle Scholar
  16. 16.
    Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS, Vitek MP, Gajdusek DC (1989) Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 86:7606–7610PubMedCrossRefGoogle Scholar
  17. 17.
    Green EK, Harris JM, Lemmon H, Lambert JC, Chartier-Harlin MC, St Clair D, Mann DM, Iwatsubo T, Lendon CL (2002) Are interleukin-1 gene polymorphisms risk factors or disease modifiers in AD? Neurology 58:1566–1568PubMedCrossRefGoogle Scholar
  18. 18.
    Griffin WS, Mrak RE (2002) Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer’s disease. J Leukoc Biol 72:233–238PubMedGoogle Scholar
  19. 19.
    Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE (1998) Glial–neuronal interactions in Alzheimer’s disease: the potential role of a ‘cytokine cycle’ in disease progression. Brain Pathol 8:65–72PubMedCrossRefGoogle Scholar
  20. 20.
    Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL 3rd, Araoz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86:7611–7615PubMedCrossRefGoogle Scholar
  21. 21.
    Grimaldi LM, Casadei VM, Ferri C, Veglia F, Licastro F, Annoni G, Biunno I, De Bellis G, Sorbi S, Mariani C, Canal N, Griffin WS, Franceschi M (2000) Association of early-onset Alzheimer’s disease with an interleukin-1alpha gene polymorphism. Ann Neurol 47:361–365PubMedCrossRefGoogle Scholar
  22. 22.
    Hayes A, Green EK, Pritchard A, Harris JM, Zhang Y, Lambert JC, Chartier-Harlin MC, Pickering-Brown SM, Lendon CL, Mann DM (2004) A polymorphic variation in the interleukin 1A gene increases brain microglial cell activity in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 75:1475–1477PubMedCrossRefGoogle Scholar
  23. 23.
    Hedley R, Hallmayer J, Groth DM, Brooks WS, Gandy SE, Martins RN (2002) Association of interleukin-1 polymorphisms with Alzheimer’s disease in Australia. Ann Neurol 51:795–797PubMedCrossRefGoogle Scholar
  24. 24.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRefGoogle Scholar
  25. 25.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560PubMedCrossRefGoogle Scholar
  26. 26.
    Hu JL, Li G, Zhou DX, Zou YX, Zhu ZS, Xu RX, Jiang XD, Zeng YJ (2009) Genetic analysis of interleukin-1A C(-889)T polymorphism with Alzheimer disease. Cell Mol Neurobiol 29:81–85PubMedCrossRefGoogle Scholar
  27. 27.
    Infante J, Llorca J, Mateo I, Rodriguez-Rodriguez E, Sanchez-Quintana C, Sanchez-Juan P, Fernandez-Viadero C, Pena N, Berciano J, Combarros O (2007) Interaction between poly(ADP-ribose) polymerase 1 and interleukin 1A genes is associated with Alzheimer’s disease risk. Dement Geriatr Cogn Disord 23:215–218PubMedCrossRefGoogle Scholar
  28. 28.
    Infante J, Sanz C, Fernandez-Luna JL, Llorca J, Berciano J, Combarros O (2004) Gene-gene interaction between interleukin-1A and interleukin-8 increases Alzheimer’s disease risk. J Neurol 251:482–483PubMedCrossRefGoogle Scholar
  29. 29.
    Ki CS, Na DL, Kim DK, Kim HJ, Kim JW (2001) Lack of association of the interleukin-1alpha gene polymorphism with Alzheimer’s disease in a Korean population. Ann Neurol 49:817–818PubMedCrossRefGoogle Scholar
  30. 30.
    Kuo YM, Liao PC, Lin C, Wu CW, Huang HM, Lin CC, Chuo LJ (2003) Lack of association between interleukin-1alpha polymorphism and Alzheimer disease or vascular dementia. Alzheimer Dis Assoc Disord 17:94–97PubMedCrossRefGoogle Scholar
  31. 31.
    Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC (1992) Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 327:248–254PubMedCrossRefGoogle Scholar
  32. 32.
    Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, Prince JA, van Duijn CM, Kehoe PG (2005) Large meta-analysis establishes the ACE insertion–deletion polymorphism as a marker of Alzheimer’s disease. Am J Epidemiol 162:305–317PubMedCrossRefGoogle Scholar
  33. 33.
    Li XQ, Zhang JW, Zhang ZX, Chen D, Qu QM (2004) Interleukin-1 gene cluster polymorphisms and risk of Alzheimer’s disease in Chinese Han population. J Neural Transm 111:1183–1190PubMedCrossRefGoogle Scholar
  34. 34.
    Licastro F, Porcellini E, Caruso C, Lio D, Corder EH (2007) Genetic risk profiles for Alzheimer’s disease: integration of APOE genotype and variants that up-regulate inflammation. Neurobiol Aging 28:1637–1643PubMedCrossRefGoogle Scholar
  35. 35.
    Mateo I, Infante J, Rodriguez E, Berciano J, Combarros O, Llorca J (2006) Interaction between dopamine beta-hydroxylase and interleukin genes increases Alzheimer’s disease risk. J Neurol Neurosurg Psychiatry 77:278–279PubMedCrossRefGoogle Scholar
  36. 36.
    Mattila KM, Rinne JO, Lehtimaki T, Roytta M, Ahonen JP, Hurme M (2002) Association of an interleukin 1B gene polymorphism (-511) with Parkinson’s disease in Finnish patients. J Med Genet 39:400–402PubMedCrossRefGoogle Scholar
  37. 37.
    McCarron MO, Stewart J, McCarron P, Love S, Vinters HV, Ironside JW, Mann DM, Graham DI, Nicoll JA (2003) Association between interleukin-1A polymorphism and cerebral amyloid angiopathy-related hemorrhage. Stroke 34:e193–e195PubMedCrossRefGoogle Scholar
  38. 38.
    Minster RL, DeKosky ST, Ganguli M, Belle S, Kamboh MI (2000) Genetic association studies of interleukin-1 (IL-1A and IL-1B) and interleukin-1 receptor antagonist genes and the risk of Alzheimer’s disease. Ann Neurol 48:817–819PubMedCrossRefGoogle Scholar
  39. 39.
    Murphy GM Jr, Claassen JD, DeVoss JJ, Pascoe N, Taylor J, Tinklenberg JR, Yesavage JA (2001) Rate of cognitive decline in AD is accelerated by the interleukin-1 alpha −889 *1 allele. Neurology 56:1595–1597PubMedCrossRefGoogle Scholar
  40. 40.
    Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar D, Love S, Moss T, Griffin WS (2000) Association of interleukin-1 gene polymorphisms with Alzheimer’s disease. Ann Neurol 47:365–368PubMedCrossRefGoogle Scholar
  41. 41.
    Nishimura M, Sakamoto T, Kaji R, Kawakami H (2004) Influence of polymorphisms in the genes for cytokines and glutathione S-transferase omega on sporadic Alzheimer’s disease. Neurosci Lett 368:140–143PubMedCrossRefGoogle Scholar
  42. 42.
    Pirskanen M, Hiltunen M, Mannermaa A, Iivonen S, Helisalmi S, Lehtovirta M, Koivisto AM, Laakso M, Soininen H, Alafuzoff I (2002) Interleukin 1 alpha gene polymorphism as a susceptibility factor in Alzheimer’s disease and its influence on the extent of histopathological hallmark lesions of Alzheimer’s disease. Dement Geriatr Cogn Disord 14:123–127PubMedCrossRefGoogle Scholar
  43. 43.
    Prince JA, Feuk L, Sawyer SL, Gottfries J, Ricksten A, Nagga K, Bogdanovic N, Blennow K, Brookes AJ (2001) Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer’s disease. Eur J Hum Genet 9:437–444PubMedCrossRefGoogle Scholar
  44. 44.
    Rebeck GW (2000) Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer’s disease. Neurosci Lett 293:75–77PubMedCrossRefGoogle Scholar
  45. 45.
    Rothwell NJ, Luheshi GN (2000) Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci 23:618–625PubMedCrossRefGoogle Scholar
  46. 46.
    Seripa D, Matera MG, Dal Forno G, Gravina C, Masullo C, Daniele A, Binetti G, Bonvicini C, Squitti R, Palermo MT, Davis DG, Antuono P, Wekstein DR, Dobrina A, Gennarelli M, Fazio VM (2005) Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients. Neurobiol Aging 26:455–464PubMedCrossRefGoogle Scholar
  47. 47.
    Serretti A, Olgiati P, Politis A, Malitas P, Albani D, Dusi S, Polito L, De Mauro S, Zisaki A, Piperi C, Liappas I, Stamouli E, Mailis A, Atti AR, Morri M, Ujkaj M, Batelli S, Forloni G, Soldatos CR, Papadimitriou GN, De Ronchi D, Kalofoutis A (2009) Lack of association between interleukin-1 alpha rs1800587 polymorphism and Alzheimer’s disease in two Independent European samples. J Alzheimers Dis 16:181–187PubMedGoogle Scholar
  48. 48.
    Tang MN, Zhang ZX, Han HY, Liu XH, Shen Y (2004) Analysis on association between the polymorphisms in apolipoprotein E, interleukin-1 alpha genes and Alzheimer’s disease in Chengdu area. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 21:176–178PubMedGoogle Scholar
  49. 49.
    Thakkinstian A, McElduff P, D’Este C, Duffy D, Attia J (2005) A method for meta-analysis of molecular association studies. Stat Med 24:1291–1306PubMedCrossRefGoogle Scholar
  50. 50.
    Tsai SJ, Liu HC, Liu TY, Wang KY, Hong CJ (2003) Lack of association between the interleukin-1alpha gene C(−889)T polymorphism and Alzheimer’s disease in a Chinese population. Neurosci Lett 343:93–96PubMedCrossRefGoogle Scholar
  51. 51.
    Vendramini AA, de Labio RW, Rasmussen LT, Dos Reis NM, Minett T, Bertolucci PH, de Souza Pinhel MA, Souza DR, Mazzotti DR, de Arruda Cardoso Smith M, Payao SL (2011) Interleukin-8-251T > A, Interleukin-1alpha-889C > T and Apolipoprotein E polymorphisms in Alzheimer’s disease. Genet Mol Biol 34:1–5PubMedCrossRefGoogle Scholar
  52. 52.
    Wang HK, Hsu WC, Fung HC, Lin JC, Hsu HP, Wu YR, Hsu Y, Hu FJ, Lee-Chen GJ, Chen CM (2007) Interleukin-1alpha and -1beta promoter polymorphisms in Taiwanese patients with dementia. Dement Geriatr Cogn Disord 24:104–110PubMedCrossRefGoogle Scholar
  53. 53.
    Xin XY, Ding JQ, Chen SD (2010) Apolipoprotein E promoter polymorphisms and risk of Alzheimer’s disease: evidence from meta-analysis. J Alzheimers Dis 19:1283–1294PubMedGoogle Scholar
  54. 54.
    Zhou YT, Zhang ZX, Zhang JW, He XM, Xu T (2006) Association between interleukin-1 alpha-889 C/T polymorphism and Alzheimer’s disease in Chinese Han population. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 28:186–190PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Xue Qin
    • 1
  • Qiliu Peng
    • 1
  • Zhiyu Zeng
    • 2
  • Zhiping Chen
    • 3
  • Liwen Lin
    • 1
  • Yan Deng
    • 1
  • Xiamei Huang
    • 1
  • Juanjuan Xu
    • 1
  • Huiling Wu
    • 1
  • Shan Huang
    • 1
  • Shan Li
    • 1
  • Jinmin Zhao
    • 4
  1. 1.Department of Clinical LaboratoryFirst Affiliated Hospital of Guangxi Medical UniversityNanningPeople’s Republic of China
  2. 2.Department of GeriatricsFirst Affiliated Hospital of Guangxi Medical UniversityNanningPeople’s Republic of China
  3. 3.Department of Occupational Health and Environmental HealthSchool of Public Health at Guangxi Medical UniversityNanningPeople’s Republic of China
  4. 4.Department of Orthopedic Trauma SurgeryFirst Affiliated Hospital of Guangxi Medical UniversityNanningPeople’s Republic of China

Personalised recommendations